34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

October 10-12, 2018 Berlin, Germany

Conference Date: October 10, 2018    Booth C17
 

Presentations featuring NfL and Simoa Technlogy at ECTRIMS

ECTRIMS ONLINE LIBRARY 

Quanterix Presentation 
P539 International multi-site analytical validation of the Simoa NF-light assay in human serum samples from multiple sclerosis patients
J. Kuhle , C. Barro , K. Hrusovsky , L. Chang , A. Jeromin , C. Bridel , A. Bar-Or , S. Bittner , W. Brück , B. Bielekova , T. Chitnis , G. Comi , M. Comabella , G. Arrambide , X. Montalban , A. Datwani , M. Fluck , R. Fox , M. Freedman , R. Furlan , S. Gnanapavan , G. Giovannoni , E. Havari , M. Khalil , D. Leppert , H. Kropshofer , M.A. Valentin , J. Oksenberg , F.
ECTRIMS Online Library. Kuhle J. Oct 10, 2018; 228383

Additional Presentations

10    The long road to clinical application: Where do we stand with neurofilament light chain in MS?

158  Serum neurofilament light (NfL) for disease prognosis and treatment monitoring in multiple sclerosis patients: Is it ready for implementation into clinical care?

205  Plasma neurofilament light levels segregate treatment effects: Results from the IMSE studies with multiple disease modulatory drugs

213  Serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) in neuromyelitis optica spectrum disorders

262  Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice

286  Neurofilament light levels in the blood of patients with secondary progressive MS are higher than in primary progressive MS and may predict brain atrophy in both MS subtypes

Posters featuring NfL and Simoa Technology 

P378   Plasma neurofilament light levels are associated with risk of developing sustained disability in multiple sclerosis

P458   Serum Neurofilament light chain concentration correlates with cognitive impairment and brain atrophy in relapsing remitting MS

P530   Relationship between serum neurofilament light chain levels and cognitive decline over 9-years follow-up in patients after first demyelinating event suggestive of MS

P532   Temporal relationship of serum neurofilament light levels and radiological disease activity in patients with multiple sclerosis

P536 CSF neurofilament light concentration reflects cognitive impairment in multiple sclerosis

P537   Ganglion cell layer volume and serum neurofilaments are associated with disability in multiple sclerosis

P666   Neurofilament light chain is a useful biomarker in paediatric multiple sclerosis

P667   Serum neurofilament light chain in pediatric acquired demyelinating syndromes

P849   Serum neurofilament light chain as a predictive marker in patients after first demyelinating event suggestive of multiple sclerosis

P852   Dimethyl fumarate decreases neurofilament light chain levels in CSF and blood

P853   Neurofilament light chain levels are a reliable and sensitive biomarker that can detect subclinical neuroinflammation in monozygotic twins discordant for multiple sclerosis

P897   Dynamic of neurofilament light chains after cessation of natalizumab in patients with relapsing remitting and secondary progressive multiple sclerosis

P1008 Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study

P1016 Multiple sclerosis diagnosis is not the only determinant of neurofilament light protein fluctuations in serum

P1116  Serum neurofilament light chain correlates with cortical lesion load at 3T and 7T in early RRMS patients

P1170 Normative values of serum neurofilament light levels

P1172 Serum GFAP associates with neurofilament light and disease severity in late multiple sclerosis

P1173 Neurofilament light chain serum concentration reflects disease severity in patients with MOG-Ab associated disorders

P1174 Strategic platform selection and validation of biomarker assays to measure serum neurofilament light and heavy chain in multiple sclerosis

P1183 Cerebrospinal fluid markers indicate glial activation and neuroaxonal damage in patients with primary progressive multiple sclerosis

P1227 An integral measure of serial neurofilament light chain assessments in blood is a predictor of long-term disability progression in relapsing-remitting multiple sclerosis

EP1571 Characterization of serum neurofilament, a biomarker for axonal damage, in the SYNERGY study as a complement to opicinumab zreatment effect in MS

EP1557 Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients

EP1600 Neuronal and glial CSF biomarkers in patients with Secondary Progressive Multiple Sclerosis treated with dimethyl fumarate

EP1609 Ozanimod (RPC1063) reduces the plasma biomarker neurofilament light chain in preclinical rodent models of multiple sclerosis

EP1613 Serum Neurofilament light chain as a predictor of long-term outcomes in patients with CIS in the BENEFIT 11 trial

P1747 Alemtuzumab reduces serum neurofilament light chain levels in relapsing-remitting multiple sclerosis patients from the CARE-MS I study

P1750 Serum neurofilament light chain levels and cortical pathology in multiple sclerosis: 5-year longitudinal study P1759 Serum neurofilament light chain and glial fibrillary acid protein analysis in patients with multiple sclerosis: A clue to distinguish inflammation and neurodegeneration?

P1766 Pilot study: Profiling of individual responses to alemtuzumab immune reconstitution treatment by high frequency serum neurofilament light assessment in highly active RRMS patients up to 102 months can pre-identify clinical and MRI disease activity

P1793 Blood neurofilament light chain levels are elevated in paediatric patients with multiple sclerosis and reduced under disease-modifying treatment